11th International Congress on Targeted Anticancer Therapies Paris, March 4-6, 2013 IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING

First Page		Document Content
Triazines Epigenetics Hypomethylating agent DNA methyltransferase Decitabine Azacitidine DNA methylation Methylation Cell culture Biology Chemistry Nucleosides		11th International Congress on Targeted Anticancer Therapies Paris, March 4-6, 2013 IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 917,51 KB Share Document on Facebook

	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma DocID: 15uOM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: 13My6 - View Document
$June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As$	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As DocID: 11odm - View Document
	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) DocID: 10gfI - View Document
$DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML$	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML DocID: Z1WQ - View Document